Silver Book Fact

New Medicines in Development for Parkinson’s Disease in 2018

Fact image

America's Biopharmaceutical Companies. Medicines in Development for Neurological Disorders: 2018 Report. Washington, D.C.: PhRMA; 2018. https://www.phrma.org/report/medicines-in-development-for-neurological-disorders-2018-report. Accessed June 11, 2019

Reference

Title
Medicines in Development for Neurological Disorders: 2018 Report
Publication
PhRMA
Publisher
PhRMA
Publication Date
2018
Authors
America's Biopharmaceutical Companies
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A current drug in development addresses the underlying cause of type 2 diabetes by modulating genes responsible for insulin sensitization.  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease by $20 billion…  
  • Studies have shown that active medical management of Alzheimer’s disease can significantly improve quality-of-life for the individual through all stages of the disease.  
  • In one study, despite a 4-fold increase in prescription drug spending, overall health spending for Alzheimer’s patients undergoing drug therapy went down by 1/3.